Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014 On August 12, 2014

BOULDER, Colo., July 28, 2014  Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information


Tuesday, August 12, 2014


9:00 a.m. Eastern Time


(800) 708-4540


(847) 619-6397

Pass Code:


Webcast, including Replay and Conference Call Slides: 

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis).  For more information on Array, please go to


Tricia Haugeto

Array BioPharma Inc.

(303) 386-1193

Logo -  

SOURCE Array BioPharma Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.